Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: The Safe, Simple Transitions (SST) study
Authors:
- Roger M. MillsRMRoger M. Mills
- Richard D. BerkowitzRBRichard D. Berkowitz
- C.V. DamarajuCDC.V. Damaraju
- Lisa K. JenningsLJLisa K. Jennings
- Peter WildgoosePWPeter Wildgoose
- 1 November 2012
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 130 (5) , 709-715
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialThe Lancet, 2009
- Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and HumansDrug Metabolism and Disposition, 2009
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialThe Lancet, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjectsEuropean Journal of Clinical Pharmacology, 2005
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology & Therapeutics, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005